Venus Medtech focuses on the R&D of transvascular intervention device
Total raised: $37M
Investors 4
| Date | Name | Website |
| - | Qiming Ven... | qimingvent... |
| - | New Age Ve... | newagevent... |
| - | Qiming Ven... | qimingvc.c... |
| - | Cowin Capi... | cowincapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.03.2016 | - | $37M | Goldman Sa... |
Mentions in press and media 12
| Date | Title | Description |
| 08.09.2024 | Venus Medtech's Venus-Vitae: A New Dawn in Heart Valve Technology | In the world of medical innovation, every breakthrough can feel like a new dawn. Recently, Venus Medtech (Hangzhou) Inc. stepped into the spotlight with its next-generation transcatheter aortic valve replacement (TAVR) system, Venus-Vitae. ... |
| 05.09.2024 | Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study | HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house d... |
| 05.09.2024 | Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study | HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house d... |
| 14.06.2024 | Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S. | HANGZHOU, China, June 14, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that its in-house developed innovative tran... |
| 05.02.2024 | Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval | HANGZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that, VenusP-Valve, the company's in-house d... |
| 18.05.2018 | Venus Medtech Receives Equity Investment from DCP Capital | Venus Medtech, a Hangzhou, China-based heart valve technology developer, received an investment from DCP Capital. The amount of the deal was not disclosed. The company intends to use the funds to invest in R&D, production, and sales net... |
| 16.05.2018 | Term Sheet — Wednesday, May 16 | CRYPTO UNICORN Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop But another reason is that this space is getting bigger, blockchain-focused companies are raising serious amounts of capital (ye... |
| 28.03.2016 | Daily funding roundup - March 28, 2016 | Emulate secured $28M; Goldman Sachs invested in Venus Medtech; Fixt received $600k Seed funding Flyr, a San Francisco, CA-based travel and data science company, received an investment from JetBlue Technology Ventures, the new venture capita... |
| 28.03.2016 | Venus Medtech Receives $37M Investment from Goldman Sachs | Venus Medtech (Hangzhou) Inc., a Hangzhou, China-based transcatheter cardiac valve developer, received a $37m investment from Goldman Sachs. The amount of the deal was not disclosed. The investment will support the company’s R&D as well... |
| 25.03.2016 | Goldman Sachs throws in $37M with Chinese replacement heart valve maker Venus Medtech | The A-Valve is the only TAVR device that meets China Food & Drug Administration requirements. The Venus P-valve pulmonary replacement has already been implanted in more than 40 patients, and the current goal is to win CE Mark approval. ... |
Show more